Total Payments
$101,072
2024 Payments
$1,346
Companies
51
Transactions
1,147
Medicare Patients
3,900
Medicare Billing
$867,697
Payment Breakdown by Category
Other$41,674 (41.2%)
Food & Beverage$20,634 (20.4%)
Research$19,018 (18.8%)
Travel$9,531 (9.4%)
Consulting$9,449 (9.3%)
Education$740.56 (0.7%)
Gifts$24.39 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $28,274 | 24 | 28.0% |
| Food and Beverage | $20,634 | 1,048 | 20.4% |
| Unspecified | $19,018 | 5 | 18.8% |
| Honoraria | $13,400 | 5 | 13.3% |
| Travel and Lodging | $9,531 | 44 | 9.4% |
| Consulting Fee | $9,449 | 5 | 9.3% |
| Education | $740.56 | 14 | 0.7% |
| Gift | $24.39 | 2 | 0.0% |
Payments by Type
General
$82,053
1,142 transactions
Research
$19,018
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Acorda Therapeutics, Inc | $31,770 | 56 | $0 (2020) |
| ACADIA Pharmaceuticals Inc | $20,361 | 89 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $14,983 | 145 | $0 (2023) |
| Amneal Pharmaceuticals LLC | $11,917 | 50 | $0 (2024) |
| US WorldMeds, LLC | $7,323 | 50 | $0 (2020) |
| Abbott Laboratories | $3,207 | 40 | $0 (2024) |
| ABBVIE INC. | $1,775 | 109 | $0 (2024) |
| Allergan, Inc. | $911.71 | 90 | $0 (2022) |
| Avanir Pharmaceuticals, Inc. | $761.77 | 53 | $0 (2019) |
| Eisai Inc. | $577.86 | 26 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,346 | 67 | ABBVIE INC. ($464.72) |
| 2023 | $4,152 | 124 | Abbott Laboratories ($1,797) |
| 2022 | $2,568 | 107 | Teva Pharmaceuticals USA, Inc. ($522.51) |
| 2021 | $1,633 | 79 | Teva Pharmaceuticals USA, Inc. ($460.59) |
| 2020 | $3,285 | 88 | Acorda Therapeutics, Inc ($1,172) |
| 2019 | $62,192 | 193 | Acorda Therapeutics, Inc ($30,508) |
| 2018 | $3,098 | 217 | Novartis Pharmaceuticals Corporation ($307.19) |
| 2017 | $22,799 | 272 | Teva Pharmaceuticals USA, Inc. ($12,686) |
All Payment Transactions
1,147 individual payment records from CMS Open Payments — Page 1 of 46
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $6.55 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/12/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $12.72 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/11/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $11.60 | General |
| Category: NEUROLOGY | ||||||
| 12/06/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/06/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/05/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $8.04 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/02/2024 | Medtronic, Inc. | PERCEPT PC BRAINSENSE (Device) | Food and Beverage | In-kind items and services | $68.74 | General |
| Category: Deep Brain Neurostimulation | ||||||
| 11/27/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $28.91 | General |
| Category: NEUROLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: NEUROSCIENCE | ||||||
| 11/20/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: NEUROLOGY | ||||||
| 11/20/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/19/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $10.80 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/31/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $6.68 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/16/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $9.02 | General |
| Category: NEUROSCIENCE | ||||||
| 10/09/2024 | Amneal Pharmaceuticals LLC | — | Food and Beverage | In-kind items and services | $25.53 | General |
| 10/04/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $6.27 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 09/30/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Musculoskeletal | ||||||
| 09/30/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $43.64 | General |
| Category: Neuropsychiatry | ||||||
| 09/18/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $25.92 | General |
| Category: NEUROLOGY | ||||||
| 09/11/2024 | ABBVIE INC. | DUOPA (Drug) | Food and Beverage | In-kind items and services | $25.07 | General |
| Category: NEUROSCIENCE | ||||||
| 09/04/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $22.07 | General |
| Category: NEUROLOGY | ||||||
| 09/04/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 09/04/2024 | Amneal Pharmaceuticals LLC | ONGENTYS 50MG CAPSULES 30 (Drug) | Food and Beverage | In-kind items and services | $12.97 | General |
| Category: NEUROLOGY | ||||||
| 08/29/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $11.33 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 08/21/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $22.35 | General |
| Category: BOTOX THERAPEUTIC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACA 16-cAC-0001 | ACADIA Pharmaceuticals Inc | $19,000 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,050 | 15,561 | $971,460 | $251,648 |
| 2022 | 18 | 1,073 | 13,937 | $906,384 | $235,306 |
| 2021 | 17 | 898 | 12,605 | $820,002 | $212,487 |
| 2020 | 20 | 879 | 10,411 | $705,547 | $168,256 |
Total Patients
3,900
Total Services
52,514
Medicare Billing
$867,697
Procedure Codes
78
All Medicare Procedures & Services
78 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 312 | 592 | $243,312 | $61,850 | 25.4% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 30 | 11,862 | $225,378 | $58,728 | 26.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 214 | 368 | $204,976 | $57,583 | 28.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 110 | 110 | $87,670 | $20,501 | 23.4% |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | Office | 2023 | 12 | 2,100 | $33,600 | $8,529 | 25.4% |
| 64612 | Injection of chemical for paralysis of nerve muscles on side of face | Office | 2023 | 15 | 37 | $19,869 | $7,432 | 37.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 50 | 87 | $24,099 | $6,863 | 28.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 44 | 44 | $22,968 | $5,134 | 22.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 26 | 27 | $20,817 | $4,372 | 21.0% |
| 96116 | Exam of neurobehavioral status, first hour | Office | 2023 | 46 | 46 | $15,962 | $3,915 | 24.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 38 | 52 | $14,196 | $3,771 | 26.6% |
| 95983 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | Office | 2023 | 17 | 56 | $11,200 | $2,653 | 23.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 23 | $9,062 | $2,505 | 27.6% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Facility | 2023 | 17 | 17 | $8,381 | $1,993 | 23.8% |
| 95984 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | Office | 2023 | 13 | 35 | $6,055 | $1,452 | 24.0% |
| 99304 | Initial nursing facility care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 19 | 19 | $6,574 | $1,431 | 21.8% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 11 | 18 | $4,644 | $1,259 | 27.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 38 | 39 | $5,070 | $1,167 | 23.0% |
| 95970 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | Office | 2023 | 19 | 29 | $7,627 | $508.20 | 6.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 292 | 541 | $222,351 | $62,220 | 28.0% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 35 | 12,450 | $236,550 | $58,876 | 24.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 182 | 260 | $144,820 | $44,743 | 30.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 97 | 97 | $77,309 | $19,155 | 24.8% |
| 64612 | Injection of chemical for paralysis of nerve muscles on side of face | Office | 2022 | 16 | 35 | $18,795 | $7,096 | 37.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 34 | 39 | $20,358 | $4,976 | 24.4% |
About Dr. Miran Salgado, MD
Dr. Miran Salgado, MD is a Neurology healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699744268.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Miran Salgado, MD has received a total of $101,072 in payments from pharmaceutical and medical device companies, with $1,346 received in 2024. These payments were reported across 1,147 transactions from 51 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($28,274).
As a Medicare-enrolled provider, Salgado has provided services to 3,900 Medicare beneficiaries, totaling 52,514 services with total Medicare billing of $867,697. Data is available for 4 years (2020–2023), covering 78 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Brooklyn, NY
- Active Since 03/16/2006
- Last Updated 10/14/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1699744268
Products in Payments
- INBRIJA (Drug) $31,386
- NUPLAZID (Drug) $20,361
- RYTARY (Drug) $11,979
- AUSTEDO (Drug) $8,847
- Xadago (Drug) $6,915
- SD809-HD (Drug) $3,949
- INFINITY (Device) $1,872
- BOTOX (Biological) $1,104
- SD809-TD (Drug) $806.54
- NUEDEXTA (Drug) $714.58
- Deep Brain Stimulation (Device) $613.44
- Xeomin (Biological) $564.99
- Fycompa (Drug) $550.24
- UBRELVY (Drug) $507.46
- Rebif (Biological) $403.97
- Infinity DBS Pulse Generators (Device) $402.63
- QULIPTA (Drug) $360.90
- INGREZZA (Drug) $341.06
- Austedo XR (Drug) $334.97
- APOKYN (Drug) $332.66
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Brooklyn
Karen Blitz-Shabbir, Do, DO
Neurology — Payments: $393,441
Neurology $393,441
Miss. Larisa Syrow, Md, MD
Neurology — Payments: $182,526
Neurology $182,526
Nada Abou-Fayssal, Md, MD
Neurology — Payments: $126,065
Neurology $126,065
Robyn Wolintz, Md, MD
Neurology — Payments: $123,772
Neurology $123,772
Dr. Dmitriy Grinshpun, M.d, M.D
Neurology — Payments: $96,680
Neurology $96,680
Dr. Daryl Victor, M.d, M.D
Neurology — Payments: $60,707
Neurology $60,707